Charles Duncan
Stock Analyst at Cantor Fitzgerald
(3.53)
# 854
Out of 5,156 analysts
217
Total ratings
47.55%
Success rate
22.37%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $6.86 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $22.58 | +24.00% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $185.40 | -19.09% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $164.49 | -6.99% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $15.98 | -12.39% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $80.46 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $10.21 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $38.31 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $28.57 | +103.01% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $28.45 | +51.14% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $62.42 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.81 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $129.93 | +19.30% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.30 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $21.31 | +64.24% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $8.68 | +49.77% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.08 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.89 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $24.79 | +37.15% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $38.22 | +30.82% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $8.02 | -37.66% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.78 | +412.89% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.46 | +173.97% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $62.76 | -7.58% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.38 | +79,610.14% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $5.49 | +1,357.19% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $0.98 | +206.31% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $4.79 | +129.65% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $7.59 | +58.10% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $10.55 | +1,492.42% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $3.26 | +513.50% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $36.52 | +447.65% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $2.14 | +86.92% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $2.12 | +1,032.08% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.73 | +8,223.70% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.62 | +146.91% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $68.14 | -42.76% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $33.99 | -55.87% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.41 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $3.88 | +4,539.18% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.86
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $22.58
Upside: +24.00%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $185.40
Upside: -19.09%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $164.49
Upside: -6.99%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $15.98
Upside: -12.39%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $80.46
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.21
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $38.31
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $28.57
Upside: +103.01%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $28.45
Upside: +51.14%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $62.42
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.81
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $129.93
Upside: +19.30%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.30
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $21.31
Upside: +64.24%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $8.68
Upside: +49.77%
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.08
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.89
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $24.79
Upside: +37.15%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $38.22
Upside: +30.82%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $8.02
Upside: -37.66%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.78
Upside: +412.89%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.46
Upside: +173.97%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $62.76
Upside: -7.58%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.38
Upside: +79,610.14%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $5.49
Upside: +1,357.19%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $0.98
Upside: +206.31%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $4.79
Upside: +129.65%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $7.59
Upside: +58.10%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $10.55
Upside: +1,492.42%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $3.26
Upside: +513.50%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $36.52
Upside: +447.65%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $2.14
Upside: +86.92%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $2.12
Upside: +1,032.08%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.73
Upside: +8,223.70%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.62
Upside: +146.91%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $68.14
Upside: -42.76%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $33.99
Upside: -55.87%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.41
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $3.88
Upside: +4,539.18%